ONCOGENUITY
DEAD

Serial Number

88900009

Owner

Oncogenuity Inc.

Attorney

Devon E. White

Filing Date

May 4, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ONCOGENUITY Trademark

Serial Number: 88900009

ONCOGENUITY is a trademark filed by Oncogenuity Inc. on May 4, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Oncogenuity Inc. (3 trademarks)

2 Gansevoort Street 9th Floor
New York, NY 10014

Entity Type: 03

Trademark Details

Filing Date

May 4, 2020

Registration Date

Not Registered

Published for Opposition

August 8, 2023

Goods & Services

Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceuticals, namely, drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical preparations and in the form of subcutaneous compounds that provide controlled release, and in the form of injectable pharmaceuticals, powders, tablets, capsules, pills, caplets, liquid drops, sachets, spray, ointment, cream, gel, lotion, patch, inhaler, granule, film, suspension, infusion and suppository, capsules, and tablets of peptide nucleic acids for the treatment of cancer and oncological conditions; Oncological preparations, namely, pharmaceutical preparations for the detection, prevention, and treatment of cancer; Pharmaceutical and medicinal preparations for the treatment of cancer, cell transplants and cell transplant rejection, organ transplants and organ transplant rejection, angiogenesis, bacterial infection, peripheral blood stem cell mobilization, lymphoma, tissue regeneration, tissue repair, leukemia, drug-induced anemia, retrovirus, viral infections, hematopoietic deficit resulting from chemotherapy or radiation therapy, elevation of white blood cells; Stem cells for medical purposes; Synthetic peptides for the treatment of cancer and oncological conditions; Biological tissue cultures for medical purposes; Therapeutic products, namely, antibodies, proteins and peptide therapeutics for treating cancer and oncological conditions; Vaccine preparations; Medical assays for testing of body fluids

Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of computer platform technology, namely, development of cancer immunotherapy software platforms for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; Information technology platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; Electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 14, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 14, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 3, 2024 EXRA
SOU EXTENSION 2 GRANTED
Oct 3, 2024 EX2G
SOU EXTENSION 2 FILED
Oct 3, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 3, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 3, 2024 EXRA
SOU EXTENSION 1 GRANTED
Apr 2, 2024 EX1G
SOU EXTENSION 1 FILED
Apr 2, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 2, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 3, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 8, 2023 NPUB
PUBLISHED FOR OPPOSITION
Aug 8, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 19, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 6, 2023 CNSA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 28, 2023 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 12, 2022 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Feb 4, 2022 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 26, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 26, 2021 GNSL
SUSPENSION LETTER WRITTEN
Jul 26, 2021 CNSL
ASSIGNED TO EXAMINER
Jun 21, 2021 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2020 GNRN
NON-FINAL ACTION E-MAILED
Aug 4, 2020 GNRT
NON-FINAL ACTION WRITTEN
Aug 4, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 29, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 15, 2020 NWOS
NEW APPLICATION ENTERED
May 7, 2020 NWAP